Market Trends of Global Constipation Treatment Industry
Peripherally Acting Mu-opioid Receptor Antagonists are Expected to Attain Significant Growth in the Constipation Treatment Market During the Forecast Period
Peripherally acting mu-opioid receptor antagonists (PAMORAs) are expected to grow significantly during the forecast period. This growth is due to the availability of various types of products launched by the key players suitable for various symptoms of opioid-induced constipation (OIC) and the rise in research activities in the segment. A few of the drugs that are readily available in the market for OIC indication are methylnaltrexone (Relistor), naldemedine (Symproic), naloxegol (Movantik), and alvimopan (Entereg).
The significance of PAMORAs in treating the OIC without disturbing the analgesic benefit of opioids is anticipated to boost segment growth. For instance, according to the study published in the Journal of Neurogastroenterology and Motility in April 2024, peripherally acting μ-opioid receptor antagonists (PAMORAs) are a category of drugs developed to mitigate opioid-induced constipation (OIC) while maintaining the analgesic benefits of opioids. The OIC is a distinct form of constipation resulting from opioids interacting with the extensive network of μ-opioid receptors in the enteric system. PAMORAs antagonize Mu receptors, maintaining gastric motility and secretion, thereby relieving constipation.
Also, the high benefits associated with PAMORA drugs in treating opioid-induced constipation are anticipated to boost the segment growth during the forecast period. For instance, according to the study published in the Journal of Pain Research in July 2023, PAMORA drugs such as methylnaltrexone are an effective and well-tolerated solution for managing OIC in cancer and non-cancer patient groups. Therefore, high tolerance levels of PAMORA drugs are anticipated to increase its adoption in OIC patients, bolstering the segment growth.
Therefore, factors such as the significance of PAMORAs in treating OIC with high tolerance and efficacy are anticipated to boost segment growth during the forecast period.
North America is Expected to Hold a Significant Market Share in the Constipation Treatment Market During the Forecast Period
North America is expected to hold a significant share of the global constipation treatment market, and it is mainly driven by the increasing prevalence of chronic constipation, the rising prevalence of irritable bowel syndrome, and growing investment in healthcare.
For instance, according to the International Foundation for Gastrointestinal Disorders 2023, in the United States, between 25 and 45 million people suffer from irritable bowel syndrome (IBS), including two-thirds of female and one-third of male patients currently. Therefore, such a huge prevalence of irritable bowel syndrome is anticipated to drive the adoption of increased stool frequency and improved stool consistency among IBS chronic constipation patients, thereby increasing the demand for effective treatment and fueling the target market growth during the forecast period.
Also, the United States holds a significant share in North America owing to factors such as the presence of a large number of market players manufacturing medications for constipation. Additionally, several market players are engaged in product launches, contributing to the region's growth. In April 2022, Ardelyx Inc. received the United States Food and Drug Administration (USFDA) for IBSRELA. This is an NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Therefore, the rising prevalence of irritable bowel syndrome and constipation, along with rising initiatives from the key market players, is anticipated to drive market growth in the region.
